Latest studies
- Active not recruitingPHASE3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
This study is looking into the long-term effects and safety of a medicine called mirikizumab for people with Crohn's disease. Participants have already taken part in a related study, and this new study will help us understand how the medicine works over a longer period.
Crohn's DiseaseRussia - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseRussia - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
Crohn's DiseaseRussia - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerRussia - Active not recruitingPHASE3
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
This study compares two treatments, risankizumab and ustekinumab, for adults with moderate to severe Crohn's disease. Researchers want to see which treatment works best to reduce Crohn's symptoms. Both treatments are given initially by IV, then by injection.
Crohn's Disease (CD)Russia - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseRussia - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
Rheumatoid ArthritisRussia - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study looks at the long-term effects and safety of a drug called mirikizumab for people with moderate to severe ulcerative colitis. It can last up to three years, with a chance to continue treatment afterward.
Ulcerative ColitisRussia - Active not recruitingPHASE3
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
This study looks at a new drug, apalutamide, combined with standard hormone therapy for men with high-risk prostate cancer before and after surgery. It aims to see if this combination helps shrink the cancer more and prevents it from spreading, compared to hormone therapy alone.
Prostatic NeoplasmsRussia - Active not recruitingPHASE3
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
This study is testing a new combination treatment for advanced bowel cancer. It compares a new medicine (S95005) with an existing one (capecitabine), both given with bevacizumab. The aim is to see if the new combination works better for patients who can't have intensive chemotherapy.
Metastatic Colorectal CancerRussia - Active not recruitingPHASE3
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
This study is testing a new combination treatment for a type of bladder cancer that hasn't spread deep into the bladder wall. It's comparing a new drug called Durvalumab with the standard treatment to see if it's more effective and safe.
Non-muscle-invasive Bladder CancerRussia - Active not recruitingPHASE3
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
This study looks at two different medicines, T-DXd and T-DM1, for certain people with HER2-positive breast cancer. It's for those who still have some cancer after their first treatments. We want to see if T-DXd works better at stopping the cancer from coming back.
HER2-Positive Primary Breast CancerResidual Invasive Breast CancerRussia - Active not recruitingPHASE3
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
This study looks at a new drug, apalutamide, for men with prostate cancer that hasn't spread but is resistant to standard treatment. It aims to see if the drug can stop the cancer from spreading and if it's safe to use.
Prostatic NeoplasmsRussia - Active not recruitingPHASE3
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
This study is looking at a new treatment for men with prostate cancer that has spread and is responding to hormone therapy. It combines a drug called niraparib with standard treatments (abiraterone acetate and prednisone) to see if it works better for those with specific genetic changes.
Metastatic Castration-sensitive Prostate CancerRussia - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
This study is testing a new combination of medicines, Giredestrant and Palbociclib, for advanced breast cancer. It's for people whose cancer is hormone-sensitive (ER-positive) but not HER2-positive. Researchers want to see if this new combination works better and is safer than a standard treatment.
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerRussia - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This study looks at a new combination of drugs, cabozantinib and atezolizumab, for men with prostate cancer that has spread and is no longer responding to hormone therapy. It compares this new combination with standard hormone treatments to see if it works better.
Metastatic Prostate CancerProstate AdenocarcinomaRussia - Active not recruitingPHASE2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
This study is for men with prostate cancer who are already taking enzalutamide as part of another research study. It aims to gather more information on the long-term safety of enzalutamide when it's helping them. Participants will continue their current treatment and have regular check-ups.
Prostate CancerRussia - Active not recruitingPHASE3
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
This study looks at a drug called Olaparib for women with a specific type of ovarian cancer. It's for those whose cancer has improved after chemotherapy and have a change in their BRCA gene. We want to see if Olaparib helps keep the cancer away longer.
Platinum SensitiveBRCA MutatedRelapsed Ovarian CancerFollowing Complete or Partial Response to Platinum Based ChemotherapyRussia - Active not recruitingPHASE3
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
This study compares a new drug, cabozantinib, with a dummy drug (placebo) for differentiated thyroid cancer that has continued to grow despite previous treatments. It aims to see if cabozantinib can slow down the cancer's progression.
Differentiated Thyroid CancerRussia - Active not recruitingPHASE2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
This study looks at a new treatment called trastuzumab deruxtecan (T-DXd) for several types of advanced cancer where a protein called HER2 is present. Researchers want to see how well it works and if it's safe for people with bladder, pancreatic, and other solid tumours.
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerRussia - Active not recruitingPHASE2
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
This study is testing a new medicine called telisotuzumab vedotin for people with a specific type of advanced non-small cell lung cancer where a protein called c-Met is present. It aims to find out who benefits most and how well it works.
Non-small Cell Lung CancerRussia - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy after surgery for certain types of womb cancer (endometrial cancer). We want to see if this combination helps stop the cancer from coming back and helps people live longer compared to chemotherapy alone.
Endometrial NeoplasmsRussia - Active not recruitingPHASE3
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
This study looks at whether switching from daily tablets to monthly injections can keep HIV under control in adults. It's for people whose HIV is already well-managed with current medication, testing a new long-acting injectable treatment.
HIV InfectionsRussia - Active not recruitingPHASE3
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
This study looks at the everyday safety and effectiveness of a new medicine, deucravacitinib, for people with psoriasis who have been in previous studies. It also checks how the body responds to common vaccines while taking this medicine.
PsoriasisRussia - Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
This study tracks the health of people with Gaucher disease over time, whether or not they are receiving treatment. There's also a sub-study for pregnant women with Gaucher disease to see how their pregnancies and babies' health progress. It helps doctors learn more about the condition.
Gaucher DiseaseCerebroside Lipidosis SyndromeGlucocerebrosidase Deficiency DiseaseGlucosylceramide Beta-Glucosidase Deficiency DiseaseRussia - RecruitingPHASE2
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
This study is looking at a new medicine called tenofovir alafenamide (TAF) for children and teenagers aged 2-17 with long-term hepatitis B. It aims to see if TAF is safe and works better than a dummy medicine (placebo) and to find the right dose for different age groups.
Chronic Hepatitis BRussia - Active not recruitingPHASE3
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
This study compares a new drug combination (enfortumab vedotin plus pembrolizumab) with standard chemotherapy for bladder cancer that has spread to the muscle. It aims to see if the new combination, given before surgery, works better and is safe.
Bladder CancerRussia - Active not recruitingPHASE2, PHASE3
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called guselkumab for people with ulcerative colitis that isn't well-controlled. We want to see if it helps reduce symptoms and if it's safe to use for those with moderate to severe forms of the condition.
Ulcerative ColitisRussia - Active not recruitingPHASE2
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
This study is testing a new combination of treatments for children and teenagers with a certain type of acute myeloid leukemia (FLT3-mutated AML). It combines a drug called midostaurin with standard chemotherapy to see if it's safe and effective for these patients.
FLT3-mutated Acute Myeloid LeukemiaRussia - Active not recruitingPHASE2
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
This study explored a new combination of medicines, tepotinib and osimertinib, for people with a specific type of advanced lung cancer. It looked at whether this combination could shrink tumours, was safe, and how the body handled the drugs after their initial treatment stopped working.
Non-small Cell Lung CancerRussia - Recruiting
Effects of Oncological Treatment During Pregnancy on Mother and Child
This study looks at how cancer and its treatments during pregnancy affect mums and their babies. Researchers want to see if babies exposed to treatments like chemotherapy develop normally, and they'll also track the mothers' health.
CancerPregnancyRussia - Active not recruitingPHASE3
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
This study compares a new drug, zanubrutinib, with standard treatments (bendamustine and rituximab) for adults with previously untreated Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL). Researchers want to see which treatment works best to stop the cancer from getting worse.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRussia - Active not recruitingPHASE3
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
This study tests a new drug, Dato-DXd, for advanced breast cancer. It compares Dato-DXd to standard chemotherapy in women whose cancer is HR-positive and HER2-negative and has already been treated with other chemotherapy. Researchers want to see if Dato-DXd works better.
Breast CancerRussia - Active not recruitingPHASE3
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
This study is looking at three new medicines for advanced melanoma, a type of skin cancer. It aims to see if combining these medicines helps people with melanoma that has spread and has a specific gene change called 'BRAF'.
MelanomaRussia - Active not recruitingPHASE3
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
This study looks at adding a drug called ribociclib to standard hormone therapy for people with early-stage breast cancer. It aims to see if this combination works better at preventing cancer from coming back and if it's safe for patients.
Early Breast CancerRussia - Active not recruitingPHASE3
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study looks at a new drug, Pirtobrutinib, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares Pirtobrutinib to standard treatments to see if it works better for those who have already tried other therapies.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRussia - Active not recruitingPHASE3
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
This study looks at a medicine called remibrutinib for chronic hives. It checks how well it works and if it's safe for people who already took part in earlier studies. It also helps make sure participants can continue getting the medicine if they need it.
Chronic Spontaneous UrticariaRussia - Active not recruitingPHASE3
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
This study compares two medicines, X-396 (ensartinib) and crizotinib, for people with a specific type of lung cancer called ALK-positive non-small cell lung cancer. It looks at how well each medicine works and if they are safe.
Non-small Cell Lung CancerRussia - RecruitingPHASE3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
This study is testing a new medicine, Masitinib, for people with Motor Neurone Disease (ALS). It aims to see if Masitinib, when taken with the usual medicine Riluzole, can help slow down the disease compared to taking Riluzole with a dummy pill.
Amyotrophic Lateral SclerosisRussia - Active not recruitingPHASE2
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
This study looks at new treatments for advanced bladder cancer that can’t be removed by surgery and where standard chemotherapy isn't an option. It tests two drugs, Durvalumab and Olaparib, to see if they are safe and effective.
Urinary Bladder NeoplasmsRussia - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
This study looks at the long-term safety and effectiveness of a medicine called Upadacitinib for people with ulcerative colitis. It's for those who haven't fully responded to previous treatment or have completed an earlier study.
Ulcerative Colitis (UC)Russia - RecruitingPHASE1, PHASE2
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
This study is looking at a medicine called asciminib for children and teenagers (1 to 17 years old) with a type of blood cancer called CML. Researchers want to find the right dose for different ages and check how safe the medicine is, especially for those who have tried other similar treatments.
Myeloid Leukemia, Philadelphia PositiveRussia - Active not recruitingPHASE4
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
This study looks at two different doses of a drug called cabozantinib for a type of thyroid cancer called medullary thyroid cancer (MTC) that has spread and is getting worse. We want to see if a lower dose works just as well with fewer side effects.
Medullary Thyroid CancerRussia - Active not recruitingPHASE2
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
This study looks at a new drug, erdafitinib, for people with a type of bladder cancer called urothelial cancer that has spread or can't be removed by surgery. It aims to see how well it works and if it's safe, specifically for those with certain genetic changes in their cancer.
Urothelial CancerRussia - Active not recruitingPHASE3
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
This study is for people who have already been taking a medicine called venetoclax for their cancer in another trial. It allows them to keep taking venetoclax if it's helping them and they're not having bad side effects, so doctors can learn more about its long-term safety.
Chronic Lymphocytic LeukemiaAcute Myeloid LeukemiaMultiple MyelomaNon-Hodgkin's LymphomaRussia - Active not recruitingPHASE3
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
This study looks at the long-term safety of a medicine called filgotinib for adults with ulcerative colitis. It's for people who have already been in another filgotinib study. The main goal is to see if taking filgotinib over a longer time is safe.
Ulcerative ColitisRussia - Active not recruitingPHASE3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
This study is for men with cancer who are already taking darolutamide in another Bayer study and are doing well. It lets them keep taking the same medicine at the same dose, continuing their treatment journey under medical supervision.
CancerRussia - Active not recruitingPHASE3
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
This study is looking at new ways to treat early-stage lung cancer that hasn't spread. It's testing if a drug called durvalumab, or another drug called osimertinib, when given after standard radiation therapy, can help improve outcomes for patients.
Carcinoma, Non-Small-Cell LungRussia - Active not recruitingPHASE3
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
This study compares a new drug, pirtobrutinib, with existing approved treatments for people with a type of blood cancer called mantle cell lymphoma (MCL). It's for patients who have already had at least one treatment and are looking for other options.
Lymphoma, Mantle-CellRussia - Active not recruitingPHASE2
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
This study is testing a new use for olaparib, a medicine to treat advanced cancers that have specific gene changes. It's for people whose cancer hasn't responded to usual treatments and has gene faults linked to how cells repair themselves.
Advanced Solid NeoplasmsRussia